Find syndicated market insights and custom brand analyses through our services offered in the rheumatology market. Spherix’s independent research is conducted by our intelligence teams in collaboration with our proprietary network of rheumatologists, patients, and leading KOLs.
Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies...
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing...
